When was Epineuron founded?

Epineuron was founded in 2016 and raised its 1st funding round 4 years after it was founded.

Where is Epineuron located?

Epineuron is headquartered in Hamilton, Canada. It is registered at 490 Piccadilly St., Apt. 2, London.

Who is the current CEO of Epineuron?

Sergio Aguirre of Epineuron. They have also founded 1 company.

How many employees does Epineuron have?

As of Apr 30, 2026, the latest employee count at Epineuron is 15.

Is Epineuron a funded company?

Epineuron is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on May 28, 2020.

When was the latest funding round of Epineuron?

Epineuron's latest funding was a $***** Seed round on May 28, 2020, with participation from 2 investors. Its primary sector is Neurology. In Canada, the Neurology sector has seen $176M in funding in 2026 to date.

Where does Epineuron rank among its competitors?

Epineuron ranks 5th amongst 16 active competitors, of which 8 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Renerva, which secured $325K in Sep, 2025.

Who are the top competitors of Epineuron?

Epineuron's top competitors include AxoGen, Tulavi Nerve Therapeutics and RxFunction. Among them, Renerva secured the most recent funding round in September, 2025.

Epineuron - 2026 Company Profile, Team, Funding & Competitors

Epineuron is a seed company based in Hamilton (Canada), founded in 2016 by Mike Willand D and Sergio Aguirre. It operates as a Provider of medical devices for peripheral nerve injury treatment. Epineuron has raised an undisclosed amount in funding from Ontario Brain Institute and Ontario Centre of Innovation. The company has 16 active competitors, including 8 funded and 1 that has exited. Its top competitors include companies like AxoGen, Tulavi Nerve Therapeutics and RxFunction.

Company Details

Epineuron Technologies provides medical devices for peripheral nerve injury treatment. It is involved in the treatment of transection, crush, compression, traction, and ischemia causing physical disability. The technology is used for the electrical stimulation of nerves for bosting the natural biochemical process for healing and repair.

Website: www.epineurontech.com/
Social
Email ID: *****@epineurontech.com
Registered Address: 490 Piccadilly St., Apt. 2, London

Key Metrics

Founded Year

2016

Location

Hamilton, Canada

Stage

Seed

Latest Funding Round

Seed, May 28, 2020, $*****

Investors

Ontario Brain Institute & 5 more

Ranked

5^th among 16 active competitors

Employee Count

15 as on Apr 30, 2026

Similar Companies

AxoGen & 18 more

View Epineuron's full profile

Epineuron is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Epineuron Technologies Inc. CIN: 986933-6 , Canada, Active	Aug 15, 2016	-	-	-

Epineuron has raised funding over 1 round. Its latest funding round was a Seed round on May 28, 2020 for $*****. 2 investors participated in its latest round. Epineuron has 6 institutional investors.

Here is the list of recent funding rounds of Epineuron:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 28, 2020	1712596	Seed	1559020	6768754	8310558	1277538

Access funding benchmarks and valuations. Sign up today!

View details of Epineuron's funding rounds and investors

The founders of Epineuron are Mike Willand D and Sergio Aguirre. Sergio Aguirre is the CEO of Epineuron.

Here are the details of Epineuron's key team members:

Mike Willand D: Co-Founder, CTO of Epineuron.
Sergio Aguirre: Co-Founder & CEO of Epineuron.
Contact Info: 1 email address

Epineuron's Board of Directors

Epineuron's board has 5 active members. Sergio Aguirre, Frank Baylis, Anthony Arnold, Michael Willand and Ing Goping are independent board members.

Here is the list of Epineuron's board of directors:

Name	Type	Representing	Status	Duration
Sergio Aguirre	Independent board member	-	Current	9y 9m
nclgzhq	Independent board member	-	Current	1y 4m
tzknypa	Independent board member	-	Current	5y 8m
nrgwizg	Independent board member	-	Current	4y 7m
jvzdx{l	Independent board member	-	Current	4y 2m

View details of Epineuron's Founder profiles and Board Members

Epineuron's employee count trend

Epineuron has 15 employees as of Apr 26. Here is Epineuron's employee count trend over the years:

Uncover Epineuron's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Epineuron include AxoGen, Tulavi Nerve Therapeutics and RxFunction. Here is the list of Top 10 competitors of Epineuron, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AxoGen 2002, Alachua (United States), Public	Developer of therapies for the repair of peripheral nerve injuries	$62.4M	Oberland Capital, Cardinal Partners & 9 others	65/100
2nd	Tulavi Nerve Therapeutics 2020, Mountain View (United States), Series A	Developer of the therapeutic device to treat neurally mediated diseases	$11.5M	Ascension Ventures, AMED Ventures & 1 others	57/100
3rd	RxFunction 2010, Minneapolis (United States), Series B	Provider of wearable prosthesis for people with sensory peripheral neuropathy	$39.9M	Cedar Point Capital, HHS	47/100
4th	BioCircuit 2016, Atlanta (United States), Series B	Developer of non-invasive electrophysiology devices to monitor peripheral nerves	$13.6M	Masters Capital Management, GRA Venture Fund ... & 4 others	43/100
5th	Epineuron 2016, Hamilton (Canada), Seed	Provider of medical devices for peripheral nerve injury treatment	-	Ontario Centre of Innovation, Ontario Brain Institute ... & 4 others	39/100
6th	Renerva 2017, Pittsburgh (United States), Seed	Surgical solutions advancing nerve recovery, restoring hope after nerve injury	$1.28M	Defense.gov, NIH & 4 others	37/100
7th	Newrotex 2019, Oxford (United Kingdom), Funding Raised	Provider of silk-based solutions for the treatment of peripheral nerve injuries	-	MedTech Innovator, EIC Fund	34/100
8th	Monarch Bioimplants 2016, Root (Switzerland), Series B	Developer of bioimplant for peripheral nerve repair	$24.9M	Global Emerging Markets, FastTrack Ventures	34/100
9th	Micro Leads 2014, Boston (United States), Seed	Precision neuromodulation therapies using minimally-invasive, high-resolution devices for nervous system interfaces	-	America’s Seed Fund, Massachusetts Life Sciences Center ... & 4 others	32/100
10th	PhotoThera 1997, Carlsbad (United States), Deadpooled	Laser therapies	$80.5M	The Vertical Group, De Novo Ventures & 5 others	31/100